Mesothelin expression is a prognostic factor in cholangiocellular carcinoma

International Surgery

Volumn 98, Issue 2, 2013, Pages 164-169

  Nomura, Ryohei ^a   Fujii, Hiroaki ^a   Abe, Masaaki ^a   Sugo, Hiroyuki ^a   Ishizaki, Yoichi ^a   Kawasaki, Seiji ^a   Hino, Okio ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Cholangiocellular carcinoma; Immunohistochemistry; Mesothelin; Survival period

Indexed keywords

GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MESOTHELIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT TUMOR; EVALUATION STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAHEPATIC BILE DUCT; LIVER RESECTION; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; GPI-LINKED PROTEINS; HEPATECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84897141947     PISSN: 00208868     EISSN: None     Source Type: Journal    
DOI: 10.9738/INTSURG-D-13-00001.1     Document Type: Article

References (18)

1. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93(1): 136-140
2. Ho M, Bera TK, Willingham M.C., Onda M., Hassan R, FitzGerald D et al. Mesothelin expression in human lung cancer. Clin Cancer Res 2007;13(5):1571-1575
3. Dainty LA, Risinger JI, Morrison C, Chandramouli G.V., Bidus MA, Zahn C et al. Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. Gynecol Oncol 2007;105(3):563-570
4. Steinbach D, Onda M, Voigt A., Dawczynski K, Wittig S, Hassan R et al. Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells. Eur J Haematol 2007; 79(4):281-286
5. Frierson HF J.r., Moskaluk CA, Powell S.M., Zhang H., Cerilli LA, Stoler MH et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 2003;34(6):605-609
6. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003;16(3):192-197
7. Argani P, Iacobuzio-Donahue C, Ryu B., Rosty C, Goggins M, Wilentz RE et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001;7(12):3862-3868
8. Hassan R, Laszik ZG, Lerner M, Raffeld M., Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 2005;124(6):838-845
9. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10(12 Pt 1):3937-3942
10. Chang K, Pai LH, Batra J.K., Pastan I., Willingham MC Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res 1992;52(1):181-186
11. Watanabe H, Okada G, Ohtsubo K., Yamaguchi Y, Mouri H, Motoo Y et al. Expression of Mesothelin mRNA in pure pancreatic juice from patients with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pancreas, and chronic pancreatitis. Pancreas 2005;30(4):349-354
12. Iacobuzio-Donahue C.A., Ashfaq R, Maitra A., Adsay NV, Shen-Ong GL, Berg K et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003;63(24):8614-8622
13. Liver Cancer Study Group of Japan, eds. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 5th ed. Tokyo, Japan: Kanehara Co, Ltd; 2009.
14. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27(11):1418-1428
15. Yen MJ, Hsu CY, Mao T.L., Wu TC, Roden R, Wang TL et al. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 2006;12(3 Pt 1):827-831
16. Hucl T, Brody JR, Gallmeier E, Iacobuzio-Donahue CA, Farrance I.K., Kern SE High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor-dependent MCAT motif. Cancer Res 2007;67(19):9055-9065
17. Li M, Bharadwaj U, Zhang R., Zhang S, Mu H, Fisher WE et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 2008;7(2):286-296
18. Kojima T, Oheda M, Hattori K., Taniguchi Y, Tamura M, Ochi N et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem 1995;270(37):21984-21990